– Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, Ocrevus, in reducing...
- A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p < 0.001) at 48 weeks at the highest dose tested (24 mg), without reaching...
Genentech will more than double the initial investment in a state-of-the-art biomanufacturing facility in Holly Springs to approximately $2 billion, bolstering Roche and Genentech’s...
'Sell America' fear is rising again, and this non-U.S. ETF could be a wise buy to stay diversified and invested globally while U.S. policy risks swirl.
Market rotations are as old as Wall Street itself. When capital exits overheated sectors like big tech, it often finds its way into undervalued industries ripe for rediscovery. The latest shift, away from...
– Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute – – Availability of Lunsumio VELO allows treatment aligned to people’s clinical...
– Agreement with the U.S. government addresses prescription drug costs and encourages other wealthy nations to reward biopharmaceutical innovation – – Influenza...
INDIANAPOLIS , Dec. 16, 2025 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of the new cobas ® 6800/8800 systems version 2.0 and software version 2.0.1,...
– Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant endocrine therapy advance in over 20 years – ...
– Lunsumio in combination with lenalidomide may offer an effective treatment in relapsed or refractory follicular lymphoma based on first data from single-arm cohort of Phase III CELESTIMO study –...